Recurrent copy number gains of ACVR1 and corresponding transcript overexpression are associated with survival in head and neck squamous cell carcinomas

Histopathology

Volumn 59, Issue 1, 2011, Pages 81-89

  Ambrosio, Eliane P ^a,b   Drigo, Sandra A ^b   Bérgamo, Nádia A ^c   Rosa, Fabíola E ^b   Bertonha, Fernanda B ^b   de Abreu, Francine B ^b   Kowalski, Luis P ^b   Rogatto, Silvia R ^a,b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

ACVR1; Chromosomal abnormalities; FISH; Head and neck cancer; Laryngeal carcinomas; Oral carcinomas; Pharyngeal carcinomas; QRT PCR

Indexed keywords

ACTIVIN A RECEPTOR TYPE 1; ACTIVIN RECEPTOR 1; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 2Q; CONFIDENCE INTERVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ACTIVIN RECEPTORS, TYPE I; AGED; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 2; FEMALE; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PHARYNGEAL NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; UP-REGULATION;

EID: 79960462297     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03885.x     Document Type: Article

References (36)

1. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009; 45; 324-334.
2. Timpson P, Wilson AS, Lehrbach GM, Sutherland RL, Musgrove EA, Daly RJ. Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer Res. 2007; 67; 9304-9314.
3. Ha PK, Chang SS, Glazer CA, Califano JA, Sidransky D. Molecular techniques and genetic alterations in head and neck cancer. Oral Oncol. 2009; 45; 335-339.
4. Mitelman Database of Chromosome Aberrations in Cancer (2009). Mitelman F, Johansson B, Mertens F (eds). Available at: (accessed February 2009).
5. Bérgamo NA, Rogatto SR, Poli-frederico RC et al. Comparative genomic hybridization analysis detects frequent over-representation of DNA sequences at 3q, 7p, and 8q in head and neck carcinomas. Cancer Genet. Cytogenet. 2000; 119; 48-55.
6. Bérgamo NA, da Silva Veiga LC, dos Reis PP et al. Classic and molecular cytogenetic analyses reveal chromosomal gains and losses correlated with survival in head and neck cancer patients. Clin. Cancer Res. 2005; 11; 621-631.
7. Bockmühl U, Wolf G, Schmidt S et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998; 20; 145-151.
8. Bockmühl U, Peterson I. DNA ploidy and chromosomal alterations in head and neck squamous cell carcinoma. Virchows Arch. 2002; 441; 541-550.
9. Knuutila S, Bjorkqvist AM, Autio K et al. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am. J. Pathol. 1998; 152; 1107-1123.
10. Renlund N, O'Neill FH, Zhang L, Sidis Y, Teixeira J. Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. J. Endocrinol. 2007; 195; 95-103.
11. Massagué J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000; 19; 1745-1754.
12. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim. Biophys. Acta 2009; 1792; 954-973.
13. World Health Organization (WHO). International classification of diseases for oncology, 2nd edn. Geneva: WHO, 1990.
14. Rogatto SR, Rainho CA, Zhang ZM et al. Hemangioendothelioma of bone in a patient with a constitutional supernumerary marker. Cancer Genet. Cytogenet. 1999; 110; 23-27.
15. Dracopoli NC. Current protocols in human genetics (CD version). New York: John Wiley & Sons, 2000.
16. Rosa FE, Caldeira JR, Felipes J et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum. Pathol. 2008; 39; 720-730.
17. Bustin SA, Benes V, Garson JA et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 2009; 55; 611-622.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25; 402-408.
19. Patmore HS, Ashman JN, Cawkwell L, MacDonald A, Stafford ND, Greenman J. Can a genetic signature for metastatic head and neck squamous cell carcinoma be characterised by comparative genomic hybridisation? Br. J. Cancer 2004; 90; 1976-1982.
20. Tapper J, Sarantaus L, Vahteristo P et al. Genetic changes in inherited and sporadic ovarian carcinomas by comparative genomic hybridization: extensive similarity except for a difference at chromosome 2q24-q32. Cancer Res. 1998; 58; 2715-2719.
21. Du Plessis L, Dietzsch E, Van Gele M et al. Mapping of novel regions of DNA gain and loss by comparative genomic hybridization in esophageal carcinoma in the black and colored populations of South Africa. Cancer Res. 1999; 59; 1877-1883.
22. Kumon K, Kobayashi H, Namiki T et al. Frequent increase of DNA copy number in the 2q24 chromosomal region and its association with a poor clinical outcome in hepatoblastoma: cytogenetic and comparative genomic hybridization analysis. Jpn. J. Cancer Res. 2001; 92; 854-862.
23. Inman GJ, Nicolás FJ, Callahan JF et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol. Pharmacol. 2002; 62; 65-74.
24. Lyons SK, Clarke AR. Apoptosis and carcinogenesis. Br. Med. Bull. 1997; 53; 554-569.
25. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann. Oncol. 2001; 12; 9-13.
26. Schwab M, Amler LC. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosom. Cancer 1990; 1; 181-193.
27. Myllykangas S, Knuutila S. Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett. 2006; 232; 79-89.
28. Jung B, Gomez J, Chau E et al. Activin signaling in microsatellite stable colon cancers is disrupted by a combination of genetic and epigenetic mechanisms. PLoS One 2009; 4; e8308.
29. Hashimoto O, Yamato K, Koseki T et al. The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. Cell. Signal. 1998; 10; 743-749.
30. Buijs JT, Rentsch CA, van der Horst G et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am. J. Pathol. 2007; 171; 1047-1057.
31. Craft CS, Romero D, Vary CP, Bergan RC. Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 2007; 26; 7240-7250.
32. Yang S, Lim M, Pham LK et al. Bone morphogenetic protein 7 protects prostate cancer cells from stress-induced apoptosis via both Smad and c-Jun NH2-terminal kinase pathways. Cancer Res. 2006; 66; 4285-4290.
33. Ye L, Lewis-Russell JM, Kynaston H, Jiang WG. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J. Urol. 2007; 178; 1086-1091.
34. Wong VCL, Chan PL, Bernabeu C et al. Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma. Int. J. Cancer 2008; 123; 2816-2823.
35. Schimming R, Marmé D. Endoglin (CD105) expression in squamous cell carcinoma of the oral cavity. Head Neck 2002; 24; 151-156.
36. Kyzas PA, Agnantis NJ, Stefanou D. Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Arch. 2006; 448; 768-775.